-
J.P. Morgan Raises EPS Estimates in 2012-13 On Amgen Prior to Today's Conference Call
Tuesday, June 7, 2011 - 8:11am | 128According to a recent report, J.P. Morgan has raised 2012-13 EPS estimates on Amgen (NASDAQ: AMGN) from $5.77/$5.77 to $5.82/$5.87 leading up to a 10 a.m. conference call today to discuss a recent survey J.P. Morgan conducted for the '147 trial. In the survey, J.P. Morgan talked to 25 urologist to...
-
Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib at the 16th Congress of the European Hematology Association
Tuesday, June 7, 2011 - 8:06am | 150Onyx Pharmaceuticals (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 16th Congress of the European Hematology Association Annual Meeting, June 9-12, 2011 in London, UK. "Data being presented this...
-
BioMarin Initiates Phase 3 Trial for Amifampridine Phosphate for the Treatment of LEMS
Tuesday, June 7, 2011 - 8:02am | 55BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has been dosed in the Phase 3 trial for amifampridine phosphate (3,4-diaminopyridine phosphate) for the treatment of patients with Lambert-Eaton Myasthenic Syndrome. Amifampridine phosphate received marketing...
-
Piper Jaffray Maintains Overweight on Infinity Pharmaceuticals
Tuesday, June 7, 2011 - 7:55am | 133Piper Jaffray is out with its report today on Infinity Pharmaceuticals (NASDAQ: INFI), maintaining Overweight. In a note to clients, Piper Jaffray writes, "Infinity presented 2 posters on intravenous Heat Shock Protein-90 inhibitor retaspimycin including Phase Ib data in combination with Taxotere...
-
J.P. Morgan Reiterates Rating On INCY Following ASCO
Tuesday, June 7, 2011 - 7:51am | 102J.P. Morgan is reiterating its Overweight rating on Incyte Corp. (NASDAQ: INCY) following the company's performance at ASCO. Says J.P. Morgan, “We are reiterating our OW rating on INCY following a solid overall performance at ASCO. The full data for the pivotal COMFORT-1 and -2 studies reinforce...
-
Jefferies Maintains Buy on Seattle Genetics
Tuesday, June 7, 2011 - 7:40am | 105Jefferies is out with its report today on Seattle Genetics (NASDAQ: SGEN), maintaining Buy. In a note to clients, Jefferies writes, "At ASCO, SGEN reported updated data on pivotal trials of its anti-CD30 antibody conjugate Adcetris in relapsed or refractory Hodgkin lymphoma and relapsed or...
-
Geron Presents Data from GRNOPC1 Trial at International Conferences, Recieves Clearance from FDA to Expand Eligibility Criteria
Tuesday, June 7, 2011 - 7:38am | 196Geron Corporation (Nasdaq: GERN) today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. Data on the first two patients were presented at the 2011 International Conference on...
-
J.P. Morgan Maintains Rating, PT Following Presentation By ARIA
Tuesday, June 7, 2011 - 7:36am | 132J.P. Morgan is maintaining its Overweight rating, along with its $10 price target on Ariad Pharmaceuticals (NASDAQ: ARIA) following the company's recent presentation at the ASCO Conference. Says J.P. Morgan, in its report, “We reiterate our OW rating on ARIA following presentations yesterday...
-
*isoray Acquires Exclusive Worldwide License For Liquid Iodine
Tuesday, June 7, 2011 - 7:31am | 184IsoRay, Inc. (NYSE: ISR) announced today that it has completed a license agreement with Dr. Reddy's Laboratories (NYSE: RDY) for exclusive worldwide licensing rights to Iotrex^®, a liquid iodine radiation, for use in brain cancer treatment. Iotrex^® is a critical component in the GliaSite^®...
-
Jefferies Maintains Hold Rating on United Therapeutics
Tuesday, June 7, 2011 - 7:30am | 63Jefferies is maintaining its Hold rating on shares of United Therapeutics Corp. (NASDAQ: UTHR). “Lower-than-expected 6MWD improvement with oral treprostinil in FREEDOMM, albeit hitting statistical significance, places pressure on second Ph3 study (FREEDOM-C2; data in Sept),” Jefferies writes. “We...
-
UPDATE: Citadel Securities Color on United Therapeutics Downgrade
Tuesday, June 7, 2011 - 7:30am | 146Citadel Securities, which downgraded shares of United Therapeutics Corp. (NASDAQ: UTHR), is providing some color on the stock. “We are downgrading UTHR shares to Neutral from Add following the announcement of disappointing data from the FREEDOM-M study evaluating oral treprostinil monotherapy in...
-
UPDATE: Oppenheimer Raises PT on KERYX Biopharmaceuticals to $8
Tuesday, June 7, 2011 - 7:20am | 121Oppenheimer is out with its report today on KERYX Biopharmaceuticals (NASDAQ: KERX), raising its PT from $7 to $8. In a note to clients, Oppenheimer writes, "We recently revisited our assumption behind perifosine's commercial projections, including the intellectual property associated with the...
-
Oppenehimer Initiates AEterna Zentaris At Outperform, $5.50 PT
Tuesday, June 7, 2011 - 7:11am | 24Oppenheimer has initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with an Outperform rating and $5.50 price target.
-
Brean Murray Raises PT On Incyte Corporation To $25
Tuesday, June 7, 2011 - 6:36am | 29Brean Murray Carret & Company has raised the price target on Incyte Corporation (NASDAQ: INCY) from $23 to $25 and maintains its Buy rating.
-
Oppenheimer Raises PT On KERX To $8
Tuesday, June 7, 2011 - 6:12am | 26Oppenheimer has raised the price target on KERYX Biopharmaceuticals (NASDAQ: KERX) from $7 to $8 and maintains its Outperform rating.